Yu KD - Search Results

1

Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.

Liu XY, Ma D, Xu XE, Jin X, Yu KD, Jiang YZ, Shao ZM. Liu XY, et al. Among authors: yu kd. Theranostics. 2018 Dec 8;8(22):6386-6399. doi: 10.7150/thno.29164. eCollection 2018. Theranostics. 2018. PMID: 30613307 Free PMC article.

2

Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients.

Yu KD, Liu GY, Di GH, Wu J, Lu JS, Shen KW, Shen ZZ, Shao ZM. Yu KD, et al. Breast. 2007 Jun;16(3):307-15. doi: 10.1016/j.breast.2006.12.011. Epub 2007 Feb 12. Breast. 2007. PMID: 17293115

3

Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment.

Yu KD, Di GH, Wu J, Lu JS, Shen KW, Liu GY, Shen ZZ, Shao ZM. Yu KD, et al. J Cancer Res Clin Oncol. 2008 Dec;134(12):1347-54. doi: 10.1007/s00432-008-0414-2. Epub 2008 May 17. J Cancer Res Clin Oncol. 2008. PMID: 18488249

4

Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, China.

Fan L, Zheng Y, Yu KD, Liu GY, Wu J, Lu JS, Shen KW, Shen ZZ, Shao ZM. Fan L, et al. Among authors: yu kd. Breast Cancer Res Treat. 2009 Sep;117(2):409-16. doi: 10.1007/s10549-008-0303-z. Epub 2009 Jan 20. Breast Cancer Res Treat. 2009. PMID: 19153831

5

A functional polymorphism in the promoter region of GSTM1 implies a complex role for GSTM1 in breast cancer.

Yu KD, Di GH, Fan L, Wu J, Hu Z, Shen ZZ, Huang W, Shao ZM. Yu KD, et al. FASEB J. 2009 Jul;23(7):2274-87. doi: 10.1096/fj.08-124073. Epub 2009 Feb 19. FASEB J. 2009. PMID: 19228880

6

Test of Hardy-Weinberg equilibrium in breast cancer case-control studies: an issue may influence the conclusions.

Yu KD, Di GH, Fan L, Shao ZM. Yu KD, et al. Breast Cancer Res Treat. 2009 Oct;117(3):675-7. doi: 10.1007/s10549-009-0353-x. Epub 2009 Feb 26. Breast Cancer Res Treat. 2009. PMID: 19242790 No abstract available.

7

Functional polymorphisms, altered gene expression and genetic association link NRH:quinone oxidoreductase 2 to breast cancer with wild-type p53.

Yu KD, Di GH, Yuan WT, Fan L, Wu J, Hu Z, Shen ZZ, Zheng Y, Huang W, Shao ZM. Yu KD, et al. Hum Mol Genet. 2009 Jul 1;18(13):2502-17. doi: 10.1093/hmg/ddp171. Epub 2009 Apr 7. Hum Mol Genet. 2009. PMID: 19351655

8

Concurrent hormone and radiation therapy in patients with breast cancer: how does chemotherapy affect treatment?

Yu KD, Shao ZM. Yu KD, et al. Lancet Oncol. 2009 May;10(5):442-4; author reply 445-6. doi: 10.1016/S1470-2045(09)70090-7. Lancet Oncol. 2009. PMID: 19410191 No abstract available.

9

Caution regarding genotyping methodology for a tri-allelic polymorphism in the novel breast cancer susceptibility gene NQO2.

Yu KD, Di GH, Fan L, Hu Z, Chen AX, Shao ZM. Yu KD, et al. Breast Cancer Res Treat. 2009 Dec;118(3):647-9. doi: 10.1007/s10549-009-0431-0. Epub 2009 Jun 3. Breast Cancer Res Treat. 2009. PMID: 19495956 No abstract available.

10

The immunohistochemically "ER-negative, PR-negative, HER2-negative, CK5/6-negative, and HER1-negative" subgroup is not a surrogate for the normal-like subtype in breast cancer.

Yu KD, Shen ZZ, Shao ZM. Yu KD, et al. Breast Cancer Res Treat. 2009 Dec;118(3):661-3. doi: 10.1007/s10549-009-0522-y. Breast Cancer Res Treat. 2009. PMID: 19714461 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

189 results

Search Page

Filters